Literature DB >> 15075166

Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil.

Ana Lucia Sampaio Sgambatti de Andrade1, João Guimarães de Andrade, Celina Maria Turchi Martelli, Simonne Almeida e Silva, Renato Maurício de Oliveira, Maria Selma Neves Costa, Cristina Borges Laval, Luiza Helena Vilela Ribeiro, Jose Luis Di Fabio.   

Abstract

BACKGROUND: The conjugate Haemophilus influenzae type b (Hib) vaccine has been highly efficacious in reducing type b H. influenzae meningitis. However, information is limited about its impact on childhood pneumonia after vaccine introduction into the routine programme. This study evaluated the effectiveness of Hib conjugate vaccine in the reduction of community-acquired pneumonia among infants in Central Brazil.
METHODS: A matched case-control study was built into an ongoing prospective population-based surveillance of pneumonia, enrolling 1293 participants between May 2000 and August 2001. Cases (n = 431) were children <or=2 years old hospitalized with radiologically definite pneumonia according to the World Health Organization standard criteria for the interpretation of radiographs for the diagnosis of pneumonia. Two controls (n = 862) without previous hospitalization for pneumonia were identified among children from the same neighbourhood and matched to cases by age stratum (+/-4 months). The Hib vaccination effectiveness was estimated as 1 minus odds ratio (OR).
RESULTS: The greatest risk factor for pneumonia among children <2 years of age was day-care centre attendance (P < 0.001). Of the study participants, 83.3% (1072/1287) were classified as vaccinated according to immunization card and 16.7% (215/1287) were considered unvaccinated. By using conditional logistic regression the vaccine effectiveness was estimated as 31.0% (95% CI: -9.0%, 57.0%) after adjusting for sex, previous flu-like illnesses, day-care attendance, smokers at home, house ownership, mother's education, and age as continuous variable.
CONCLUSION: Under programme conditions the effectiveness of Hib conjugate vaccine in infants with radiologically confirmed pneumonia was 31% (95% CI: -9%, 57%) showing the potential benefit of Hib immunization in the prevention of likely non-bacteraemic pneumonia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075166     DOI: 10.1093/ije/dyh025

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  14 in total

Review 1.  The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality.

Authors:  Evropi Theodoratou; Sue Johnson; Arnoupe Jhass; Shabir A Madhi; Andrew Clark; Cynthia Boschi-Pinto; Sunil Bhopal; Igor Rudan; Harry Campbell
Journal:  Int J Epidemiol       Date:  2010-04       Impact factor: 7.196

2.  Procalcitonin and C-reactive protein for invasive bacterial pneumonia diagnosis among children in Mozambique, a malaria-endemic area.

Authors:  Núria Díez-Padrisa; Quique Bassat; Sonia Machevo; Llorenç Quintó; Luis Morais; Tacilta Nhampossa; Cristina O'Callaghan-Gordo; Antoni Torres; Pedro L Alonso; Anna Roca
Journal:  PLoS One       Date:  2010-10-14       Impact factor: 3.240

Review 3.  Vaccines to prevent pneumonia in children - a developing country perspective.

Authors:  Jacquie N Oliwa; Ben J Marais
Journal:  Paediatr Respir Rev       Date:  2015-08-19       Impact factor: 2.726

4.  Vaccines to prevent pneumonia and improve child survival.

Authors:  Shabir A Madhi; Orin S Levine; Rana Hajjeh; Osman D Mansoor; Thomas Cherian
Journal:  Bull World Health Organ       Date:  2008-05       Impact factor: 9.408

5.  Pneumonia and poverty: a prospective population-based study among children in Brazil.

Authors:  Lícia K A M Thörn; Ruth Minamisava; Simonne S Nouer; Luiza H Ribeiro; Ana Lucia Andrade
Journal:  BMC Infect Dis       Date:  2011-06-22       Impact factor: 3.090

Review 6.  Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls.

Authors:  Jennifer R Verani; Abdullah H Baqui; Claire V Broome; Thomas Cherian; Cheryl Cohen; Jennifer L Farrar; Daniel R Feikin; Michelle J Groome; Rana A Hajjeh; Hope L Johnson; Shabir A Madhi; Kim Mulholland; Katherine L O'Brien; Umesh D Parashar; Manish M Patel; Laura C Rodrigues; Mathuram Santosham; J Anthony Scott; Peter G Smith; Halvor Sommerfelt; Jacqueline E Tate; J Chris Victor; Cynthia G Whitney; Anita K Zaidi; Elizabeth R Zell
Journal:  Vaccine       Date:  2017-04-22       Impact factor: 3.641

Review 7.  Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining?

Authors:  Stephen K Obaro; Shabir A Madhi
Journal:  Lancet Infect Dis       Date:  2006-03       Impact factor: 25.071

8.  Early indication for a reduced burden of radiologically confirmed pneumonia in children following the introduction of routine vaccination against Haemophilus influenzae type b in Nha Trang, Vietnam.

Authors:  Stefan Flasche; Kensuke Takahashi; Dinh Thiem Vu; Motoi Suzuki; Thi Hien-Anh Nguyen; HuuTho Le; Masahiro Hashizume; Duc Anh Dang; Karen Edmond; Koya Ariyoshi; E Kim Mulholland; W John Edmunds; Lay-Myint Yoshida
Journal:  Vaccine       Date:  2014-11-01       Impact factor: 3.641

9.  Progress in vaccination against Haemophilus influenzae type b in the Americas.

Authors:  M Carolina Danovaro-Holliday; Salvador Garcia; Ciro de Quadros; Gina Tambini; Jon K Andrus
Journal:  PLoS Med       Date:  2008-04-22       Impact factor: 11.069

Review 10.  Respiratory risks from household air pollution in low and middle income countries.

Authors:  Stephen B Gordon; Nigel G Bruce; Jonathan Grigg; Patricia L Hibberd; Om P Kurmi; Kin-bong Hubert Lam; Kevin Mortimer; Kwaku Poku Asante; Kalpana Balakrishnan; John Balmes; Naor Bar-Zeev; Michael N Bates; Patrick N Breysse; Sonia Buist; Zhengming Chen; Deborah Havens; Darby Jack; Surinder Jindal; Haidong Kan; Sumi Mehta; Peter Moschovis; Luke Naeher; Archana Patel; Rogelio Perez-Padilla; Daniel Pope; Jamie Rylance; Sean Semple; William J Martin
Journal:  Lancet Respir Med       Date:  2014-09-02       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.